Cargando…
Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data
BACKGROUND: Although sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) improve not only glycemic control but also liver inflammation and fatty changes in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM), its sustainability and effect on liver fibrosis ha...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989116/ https://www.ncbi.nlm.nih.gov/pubmed/33815743 http://dx.doi.org/10.1177/20420188211000243 |
_version_ | 1783668897537327104 |
---|---|
author | Arai, Taeang Atsukawa, Masanori Tsubota, Akihito Mikami, Shigeru Ono, Hiroki Kawano, Tadamichi Yoshida, Yuji Tanabe, Tomohide Okubo, Tomomi Hayama, Korenobu Nakagawa-Iwashita, Ai Itokawa, Norio Kondo, Chisa Kaneko, Keiko Emoto, Naoya Nagao, Mototsugu Inagaki, Kyoko Fukuda, Izumi Sugihara, Hitoshi Iwakiri, Katsuhiko |
author_facet | Arai, Taeang Atsukawa, Masanori Tsubota, Akihito Mikami, Shigeru Ono, Hiroki Kawano, Tadamichi Yoshida, Yuji Tanabe, Tomohide Okubo, Tomomi Hayama, Korenobu Nakagawa-Iwashita, Ai Itokawa, Norio Kondo, Chisa Kaneko, Keiko Emoto, Naoya Nagao, Mototsugu Inagaki, Kyoko Fukuda, Izumi Sugihara, Hitoshi Iwakiri, Katsuhiko |
author_sort | Arai, Taeang |
collection | PubMed |
description | BACKGROUND: Although sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) improve not only glycemic control but also liver inflammation and fatty changes in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM), its sustainability and effect on liver fibrosis have remained unclear. The current study aimed to clarify the effects of 48-week SGLT2-I therapy on liver inflammation, fatty changes, and fibrosis in NAFLD patients with T2DM. METHODS: This study evaluated the effects of SGLT2-I on NAFLD, including liver fibrosis assessed via transient elastography, in 56 patients with NAFLD who received SGLT2-I for 48 weeks. Moreover, changes in each clinical parameter between patients receiving SGLT2-I (the SGLT2-I group) and those receiving other oral hypoglycemic agents (OHAs) (the non-SGLT2-I group) were compared, using 1:1 propensity score matching to adjust for baseline factors. RESULTS: The SGLT2-I group exhibited a significant decrease in controlled attenuation parameter (312 dB/m at baseline to 280 dB/m at week 48) and liver stiffness measurement (9.1–6.7 kPa) (p < 0.001 for both). After propensity score matching (44 patients each in the SGLT2-I and non-SGLT2-I groups), no significant difference in HbA1c decrease was observed between the two groups. However, compared with the non-SGLT2-I group, the SGLT2-I group showed a significant decrease in body weight (p < 0.001), alanine aminotransferase (p = 0.02), uric acid (p < 0.001), and Fibrosis-4 (FIB-4) index (p = 0.01) at week 48. The improvement in FIB-4 index, defined as a ⩾10% decline from baseline at week 48, was 56.8% (25/44) in the SGLT2-I group and 20.5% (9/44) in the non-SGLT2-I group (p < 0.001). CONCLUSION: SGLT2-Is improved not only glycemic control but also liver fatty infiltration and fibrosis in patients with NAFLD and T2DM, suggesting their possible superiority to other OHAs concerning these effects. |
format | Online Article Text |
id | pubmed-7989116 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-79891162021-04-02 Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data Arai, Taeang Atsukawa, Masanori Tsubota, Akihito Mikami, Shigeru Ono, Hiroki Kawano, Tadamichi Yoshida, Yuji Tanabe, Tomohide Okubo, Tomomi Hayama, Korenobu Nakagawa-Iwashita, Ai Itokawa, Norio Kondo, Chisa Kaneko, Keiko Emoto, Naoya Nagao, Mototsugu Inagaki, Kyoko Fukuda, Izumi Sugihara, Hitoshi Iwakiri, Katsuhiko Ther Adv Endocrinol Metab Original Research BACKGROUND: Although sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) improve not only glycemic control but also liver inflammation and fatty changes in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM), its sustainability and effect on liver fibrosis have remained unclear. The current study aimed to clarify the effects of 48-week SGLT2-I therapy on liver inflammation, fatty changes, and fibrosis in NAFLD patients with T2DM. METHODS: This study evaluated the effects of SGLT2-I on NAFLD, including liver fibrosis assessed via transient elastography, in 56 patients with NAFLD who received SGLT2-I for 48 weeks. Moreover, changes in each clinical parameter between patients receiving SGLT2-I (the SGLT2-I group) and those receiving other oral hypoglycemic agents (OHAs) (the non-SGLT2-I group) were compared, using 1:1 propensity score matching to adjust for baseline factors. RESULTS: The SGLT2-I group exhibited a significant decrease in controlled attenuation parameter (312 dB/m at baseline to 280 dB/m at week 48) and liver stiffness measurement (9.1–6.7 kPa) (p < 0.001 for both). After propensity score matching (44 patients each in the SGLT2-I and non-SGLT2-I groups), no significant difference in HbA1c decrease was observed between the two groups. However, compared with the non-SGLT2-I group, the SGLT2-I group showed a significant decrease in body weight (p < 0.001), alanine aminotransferase (p = 0.02), uric acid (p < 0.001), and Fibrosis-4 (FIB-4) index (p = 0.01) at week 48. The improvement in FIB-4 index, defined as a ⩾10% decline from baseline at week 48, was 56.8% (25/44) in the SGLT2-I group and 20.5% (9/44) in the non-SGLT2-I group (p < 0.001). CONCLUSION: SGLT2-Is improved not only glycemic control but also liver fatty infiltration and fibrosis in patients with NAFLD and T2DM, suggesting their possible superiority to other OHAs concerning these effects. SAGE Publications 2021-03-21 /pmc/articles/PMC7989116/ /pubmed/33815743 http://dx.doi.org/10.1177/20420188211000243 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Arai, Taeang Atsukawa, Masanori Tsubota, Akihito Mikami, Shigeru Ono, Hiroki Kawano, Tadamichi Yoshida, Yuji Tanabe, Tomohide Okubo, Tomomi Hayama, Korenobu Nakagawa-Iwashita, Ai Itokawa, Norio Kondo, Chisa Kaneko, Keiko Emoto, Naoya Nagao, Mototsugu Inagaki, Kyoko Fukuda, Izumi Sugihara, Hitoshi Iwakiri, Katsuhiko Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data |
title | Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data |
title_full | Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data |
title_fullStr | Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data |
title_full_unstemmed | Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data |
title_short | Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data |
title_sort | effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989116/ https://www.ncbi.nlm.nih.gov/pubmed/33815743 http://dx.doi.org/10.1177/20420188211000243 |
work_keys_str_mv | AT araitaeang effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT atsukawamasanori effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT tsubotaakihito effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT mikamishigeru effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT onohiroki effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT kawanotadamichi effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT yoshidayuji effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT tanabetomohide effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT okubotomomi effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT hayamakorenobu effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT nakagawaiwashitaai effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT itokawanorio effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT kondochisa effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT kanekokeiko effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT emotonaoya effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT nagaomototsugu effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT inagakikyoko effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT fukudaizumi effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT sugiharahitoshi effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata AT iwakirikatsuhiko effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata |